This competing renewal of the Columbia University Neuroscience training grant is designed to support eight postdoctoral scientists per year in a multi-departmental training program devoted to basic neuroscience research that elucidates basic neural mechanisms associated with drugs of abuse. Sixteen faculty from basic and clinical departments with interest and expertise in this area act as mentors. Their laboratories address basic molecular steps in the reward pathway, encompassing acetylcholine, dopamine, and serotonin receptors, dopamine uptake transporters, circuitry, development, and the mechanism of action of psychostimulant drugs as well as neurotoxic and neuropsychiatric consequences that stem from the actions of these compounds. While Columbia University has a long-standing training grant to provide support for clinical research in drug abuse, this is the sole training program in basic research in drug abuse. We believe that the institution provides a strong, and in some ways unique, environment to provide an in depth focus in this area, along with a strong group of proven investigators with demonstrable records of providing first-rate guidance and training to junior investigators.

Public Health Relevance

The purpose of this proposal is to fund postdoctoral scientists in a sixteen laboratories at Columbia University Medical school to develop their scientific expertise and provide the new generation of scientists devoted to understanding the biological cause and consequences of substance abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
2T32DA016224-06A1
Application #
7869590
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Babecki, Beth
Project Start
2003-04-01
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
6
Fiscal Year
2010
Total Cost
$179,334
Indirect Cost
Name
Columbia University (N.Y.)
Department
Neurology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
McCracken, Lindsay M; Lowes, Daniel C; Salling, Michael C et al. (2017) Glycine receptor ?3 and ?2 subunits mediate tonic and exogenous agonist-induced currents in forebrain. Proc Natl Acad Sci U S A 114:E7179-E7186
Muller, Jeff M; Shair, Harry N (2016) Isolation-induced vocalization in the infant rat depends on the nucleus accumbens. Dev Psychobiol 58:1116-1123
Gallo, Eduardo F; Salling, Michael C; Feng, Bo et al. (2015) Upregulation of dopamine D2 receptors in the nucleus accumbens indirect pathway increases locomotion but does not reduce alcohol consumption. Neuropsychopharmacology 40:1609-18
Mrejeru, A; Martí-Prats, L; Avegno, E M et al. (2015) A subset of ventral tegmental area dopamine neurons responds to acute ethanol. Neuroscience 290:649-58
Gaisler-Salomon, Inna; Wang, Yvonne; Chuhma, Nao et al. (2012) Synaptic underpinnings of altered hippocampal function in glutaminase-deficient mice during maturation. Hippocampus 22:1027-39
Bendor, Jacob; Lizardi-Ortiz, José E; Westphalen, Robert I et al. (2010) AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release. EMBO J 29:2813-26
Chuhma, N; Choi, W Y; Mingote, S et al. (2009) Dopamine neuron glutamate cotransmission: frequency-dependent modulation in the mesoventromedial projection. Neuroscience 164:1068-83
Shair, Harry N; Muller, Jeff M; Moore, Holly (2009) Dopamine's role in social modulation of infant isolation-induced vocalization: I. Reunion responses to the dam, but not littermates, are dopamine dependent. Dev Psychobiol 51:131-46
Muller, Jeff M; Moore, Holly; Myers, Michael M et al. (2009) Dopamine's role in social modulation of infant isolation-induced vocalization: II. Maternally modulated infant separation responses are regulated by D1- and D2-family dopamine receptors. Dev Psychobiol 51:158-72
Gaisler-Salomon, Inna; Miller, Gretchen M; Chuhma, Nao et al. (2009) Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology 34:2305-22

Showing the most recent 10 out of 14 publications